Regeneron Announces Investor Conference Presentations
Regeneron Announces Investor Conference Presentations
TARRYTOWN, N.Y., May 06, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
纽约州塔里敦，2024年5月6日（环球新闻专线）——Regeneron Pharmicals, Inc.（纳斯达克股票代码：REGN）将通过网络直播管理层的参与情况如下：
- RBC Capital Markets Global Healthcare Conference at 9:00 a.m. ET on Tuesday, May 14, 2024
- Jefferies Global Healthcare Conference at 8:30 a.m. ET on Wednesday, June 5, 2024
- Goldman Sachs 45th Annual Global Healthcare Conference at 8:00 a.m. ET on Tuesday, June 11, 2024
- 加拿大皇家银行资本市场全球医疗保健会议将于美国东部时间2024年5月14日星期二上午9点举行
- 杰富瑞全球医疗保健会议将于美国东部时间2024年6月5日星期三上午 8:30 举行
- 高盛 45第四 年度全球医疗保健会议将于美国东部时间2024年6月11日星期二上午8点举行
The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and transcripts of the webcasts will be archived on the Company's website for at least 30 days.
可从Regeneron网站的 “投资者与媒体” 页面访问这些会议，网址为 https://investor.regeneron.com/events-and-presentations。网络广播的重播和记录将在公司网站上存档至少30天。
About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.
关于 Regeneron
Regeneron（纳斯达克股票代码：REGN）是一家领先的生物技术公司，为严重疾病患者发明、开发和商业化改变生活的药物。我们由医师兼科学家创立和领导，具有反复持续地将科学转化为医学的独特能力，促成了许多获得批准的疗法和候选产品正在开发中，其中大多数是在我们的实验室中本土研发的。我们的药物和产品线旨在帮助患有眼部疾病、过敏和炎性疾病、癌症、心血管和代谢疾病、神经系统疾病、血液系统疾病、传染病和罕见疾病的患者。
Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.
Regeneron 使用我们的专有技术突破科学发现的界限并加速药物开发，例如 Veloci 套件，它可产生优化的全人抗体和新类别的双特异性抗体。我们正在利用再生元遗传学中心的数据驱动见解塑造下一个医学前沿 以及开创性的基因医学平台，使我们能够确定可能治疗或治愈疾病的创新靶标和补充方法。
For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.
欲了解更多信息，请访问 www.regeneron.com 或者继续关注 Regeneron 领英， Instagram， Facebook 要么 X。
Contact Information:
Investor Relations
Ryan Crowe
914.847.8790
ryan.crowe@regeneron.com
联系信息：
投资者关系
Ryan Crowe
914.847.8790
ryan.crowe@regeneron.com
Source: Regeneron Pharmaceuticals, Inc.
来源：Regeneron Pharmicals, Inc.